JP2022514215A5 - - Google Patents
Info
- Publication number
- JP2022514215A5 JP2022514215A5 JP2021531947A JP2021531947A JP2022514215A5 JP 2022514215 A5 JP2022514215 A5 JP 2022514215A5 JP 2021531947 A JP2021531947 A JP 2021531947A JP 2021531947 A JP2021531947 A JP 2021531947A JP 2022514215 A5 JP2022514215 A5 JP 2022514215A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- amino acid
- binding molecule
- antigen
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775803P | 2018-12-05 | 2018-12-05 | |
| US62/775,803 | 2018-12-05 | ||
| PCT/AU2019/051330 WO2020113274A1 (en) | 2018-12-05 | 2019-12-05 | Rank antagonists and uses therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514215A JP2022514215A (ja) | 2022-02-10 |
| JP2022514215A5 true JP2022514215A5 (https=) | 2022-12-13 |
Family
ID=70974055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531947A Withdrawn JP2022514215A (ja) | 2018-12-05 | 2019-12-05 | Ｒａｎｋアンタゴニストおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220227876A1 (https=) |
| EP (1) | EP3894441A4 (https=) |
| JP (1) | JP2022514215A (https=) |
| KR (1) | KR20210110818A (https=) |
| CN (1) | CN113454116A (https=) |
| AU (1) | AU2019394364A1 (https=) |
| CA (1) | CA3121945A1 (https=) |
| WO (1) | WO2020113274A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230118573A (ko) * | 2020-11-11 | 2023-08-11 | 에이치큐 한 | 액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도 |
| US11572407B2 (en) | 2020-11-18 | 2023-02-07 | Pionyr Immunotherapeutics, Inc. | Anti-MARCO antibodies and uses thereof |
| US20250012798A1 (en) * | 2021-11-11 | 2025-01-09 | The General Hospital Corporation | Methods for defining stages and progression of amyotrophic lateral sclerosis |
| WO2024126750A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Methods for treating cancer |
| WO2024205302A1 (ko) * | 2023-03-30 | 2024-10-03 | 유노비아 주식회사 | 인터페론 알파 수용체의 변이체, 이를 포함하는 융합단백질 및 이의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003210054A1 (en) * | 2002-03-21 | 2003-10-08 | Komed Co., Ltd. | Anti-rank monoclonal antibodies and pharmaceutical composition containing the same |
| US10259878B2 (en) * | 2013-03-14 | 2019-04-16 | Apexigen, Inc. | Anti-RANKL antibodies and methods of use |
| WO2018223182A1 (en) * | 2017-06-05 | 2018-12-13 | The Council Of The Queensland Institute Of Medical Research | A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefor. |
-
2019
- 2019-12-05 AU AU2019394364A patent/AU2019394364A1/en not_active Abandoned
- 2019-12-05 CA CA3121945A patent/CA3121945A1/en active Pending
- 2019-12-05 WO PCT/AU2019/051330 patent/WO2020113274A1/en not_active Ceased
- 2019-12-05 JP JP2021531947A patent/JP2022514215A/ja not_active Withdrawn
- 2019-12-05 US US17/311,036 patent/US20220227876A1/en not_active Abandoned
- 2019-12-05 CN CN201980091415.5A patent/CN113454116A/zh active Pending
- 2019-12-05 EP EP19892881.4A patent/EP3894441A4/en not_active Withdrawn
- 2019-12-05 KR KR1020217020663A patent/KR20210110818A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514215A5 (https=) | ||
| CN111971304B (zh) | 在酸性pH结合至VISTA的抗体 | |
| IL264144B1 (en) | Antibody 18a2 against claudin and its use | |
| JP2022515318A5 (https=) | ||
| JP7269167B2 (ja) | モジュラー四価二重特異性抗体プラットフォーム | |
| JP2023145487A (ja) | 抗ｔｉｍ－３抗体のための投与レジメンおよびその使用 | |
| FI4324851T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| JP2022507295A5 (https=) | ||
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| WO2016126781A4 (en) | Tnfrsf-binding agents and uses thereof | |
| JP2017511687A5 (https=) | ||
| RS63663B1 (sr) | Imunokonjugati anti-pd-1 antitela sa mutantom il-2 ili sa il-15 | |
| JP2017516489A5 (https=) | ||
| US20240092856A1 (en) | Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules | |
| JP2021510076A (ja) | キメラ抗原受容体を発現する免疫細胞 | |
| CN112638948B (zh) | 在酸性pH下结合至VISTA的抗体 | |
| WO2018132513A1 (en) | T cells experessing a chimeric antigen receptor | |
| JP2020524157A (ja) | がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤 | |
| US20220072103A1 (en) | Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 | |
| CN121779568A (zh) | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 | |
| JP2022512326A (ja) | 腫瘍抗原、ＴＧＦ－β、および免疫チェックポイントを標的とする組み合わせＴＣＲ－Ｔ細胞療法 | |
| US20240262913A1 (en) | Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies | |
| KR20190133734A (ko) | 키메라 폴리펩티드 및 그의 세포 막 내 국재화를 변경시키는 방법 | |
| JP2021534784A5 (https=) | ||
| JP2022548292A (ja) | 酸性ｐＨでＶＩＳＴＡと結合する抗体 |